Azithromycin is a widely used broad-spectrum macrolide antibiotic derived from erythromycin but with improved pharmacokinetic properties. It is classified as an azalide, a subclass of macrolides, due to the incorporation of a nitrogen atom into the lactone ring. This structural modification enhances its acid stability, tissue penetration, and half-life, allowing for shorter dosing regimens. First approved in the early 1990s, azithromycin has become a cornerstone in the treatment of respiratory tract infections, skin and soft tissue infections, sexually transmitted diseases, and certain atypical infections.

Mechanism of Action

Azithromycin exerts its bacteriostatic effect by binding reversibly to the 50S ribosomal subunit of susceptible bacteria, specifically to the 23S rRNA in the peptidyl transferase center. This interaction inhibits mRNA translation by blocking the translocation step of protein synthesis. It prevents the peptide chain from elongating, thereby halting bacterial growth. In some cases, high concentrations can achieve bactericidal activity, particularly against Streptococcus pneumoniae and group A streptococci. The drug also demonstrates immunomodulatory effects independent of its antibacterial action, including inhibition of pro-inflammatory cytokines and reduction of neutrophil infiltration, which contribute to its efficacy in chronic inflammatory conditions such as cystic fibrosis and chronic obstructive pulmonary disease.

Antimicrobial Spectrum

Azithromycin has a broad spectrum covering many Gram-positive cocci (including Streptococcus pyogenes, S. pneumoniae, and some strains of Staphylococcus aureus), Gram-negative bacteria such as Haemophilus influenzae, Moraxella catarrhalis, Neisseria gonorrhoeae, and Chlamydia trachomatis. It is particularly effective against atypical pathogens like Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydophila pneumoniae. However, Gram-negative enteric bacteria such as Escherichia coli and Klebsiella pneumoniae are often resistant. The drug also exhibits activity against certain mycobacteria (e.g., Mycobacterium avium complex) and protozoa like Toxoplasma gondii and Plasmodium species. Importantly, macrolide resistance has emerged via ribosomal methylases (erm genes), efflux pumps (mef genes), and target site modifications, limiting efficacy in some settings.

Pharmacokinetics

Azithromycin is well absorbed orally with a bioavailability of about 37%, though food may slightly reduce absorption for some formulations. It is extensively distributed into tissues, achieving concentrations 10–100 times higher than in plasma, especially in lungs, tonsils, prostate, and macrophages. Its long elimination half-life (about 68 hours) allows once-daily dosing and short course therapy (typically 3 to 5 days). The drug is primarily eliminated unchanged in bile and feces, with only about 6% excreted renally. This pharmacokinetic profile supports high intracellular accumulation, making it effective against intracellular pathogens.

Clinical Indications

Azithromycin is approved for a variety of infections. In respiratory tract infections, it is used for acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia (including atypical pneumonia), and acute sinusitis. In otitis media, a single-dose regimen is available. For pharyngitis and tonsillitis caused by group A streptococci, it serves as an alternative for penicillin-allergic patients. In sexually transmitted infections, a single 1g oral dose is first-line for uncomplicated Chlamydia trachomatis infection and is also recommended for gonorrhea (often in combination with ceftriaxone) and non-gonococcal urethritis. Azithromycin is a key component in the management of Mycoplasma genitalium infections and is used for trachoma elimination programs via mass drug administration. Additionally, [perm24.it] it is employed for Mycobacterium avium complex prophylaxis in advanced HIV infection, for malaria chemoprevention in pregnant women (as part of intermittent preventive treatment), and for reducing exacerbations in cystic fibrosis and COPD patients due to its anti-inflammatory properties.

Adverse Effects

Azithromycin is generally well tolerated. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, abdominal pain, and vomiting. Less frequent effects include headache, dizziness, and rash. Serious adverse events are rare but include hepatotoxicity (elevated liver enzymes, jaundice), acute pancreatitis, and severe skin reactions like Stevens-Johnson syndrome. A notable concern is cardiotoxicity: azithromycin can prolong the QT interval, increasing the risk of life-threatening arrhythmias such as torsades de pointes, especially in patients with pre-existing QT prolongation, electrolyte imbalances, bradycardia, or concomitant use of other QT-prolonging drugs. The US FDA has issued warnings about this risk. Additionally, azithromycin may exacerbate myasthenia gravis and has been associated with infantile hypertrophic pyloric stenosis if given to neonates. Allergic reactions, including anaphylaxis, are possible. Drug interactions include increased effect of warfarin (monitoring INR), and potential increased risk of cardiac arrhythmias with other QT-prolonging agents.

Resistance and Ongoing Concerns

Macrolide resistance has increased globally, particularly among S. pneumoniae and group A streptococci. Resistance mechanisms include ribosomal methylation (constitutive or inducible) and active efflux. In community-acquired pneumonia, macrolide resistance rates can exceed 30% in some regions, prompting guidelines to recommend combination therapy with a beta-lactam when using azithromycin empirically. The drug's broad use in livestock and mass drug administration programs also raises concerns about fostering resistance. Despite these challenges, azithromycin remains a valuable agent because of its unique pharmacokinetics, anti-inflammatory actions, and efficacy in specific niches.

Conclusion

Azithromycin is a versatile macrolide antibiotic with distinctive pharmacokinetic advantages, a broad spectrum, and clinical utility across diverse infections. Its long half-life, excellent tissue penetration, and anti-inflammatory properties distinguish it from other antibiotics. However, judicious use is essential to minimize resistance development and adverse cardiac effects. Ongoing surveillance of resistance patterns and careful patient selection for QT interval risks are critical to preserving its role in modern medicine. As research continues, azithromycin may find new applications in immunomodulation and prophylaxis, maintaining its significance in infectious disease management.